Liminal Biosciences Inc (LMNL)
3.883
+0.07
(+1.92%)
USD |
NASDAQ |
Mar 24, 16:00
3.85
-0.03
(-0.85%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 12.05M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -61.55% |
| Valuation | |
| PE Ratio | 113.77 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 0.4518 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.97% |
News
Headline
Wire
Time (ET)
PR Newswire
03/15 16:05
Liminal BioSciences to Report Fourth Quarter and Year Ended 2022 Financial Results on March 15, 2023
PR Newswire
03/13 16:05
PR Newswire
02/15 16:05
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/11/2023* | 08:30 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 05/10/2023* | -- | Results | Q1 2023 | -- | -- | -- | |
| 03/16/2023 | 08:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 03/15/2023 | -- | Results | Q4 2022 | -- | -1.03 | -- | |
| 11/10/2022 | 08:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 11/09/2022 | -- | Results | Q3 2022 | -- | -1.11 | -- | |
| 08/10/2022 | 08:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 08/09/2022 | -- | Results | Q2 2022 | -- | -1.51 | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Liminal Biosciences Inc is a clinical stage biopharmaceutical company focused on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic, and metabolic diseases using our drug discovery platform and a data driven approach. The company has active business operations in Canada and the United Kingdom. |
| URL | https://www.liminalbiosciences.com |
| Investor Relations URL | http://www.prometic.com/investors/ |
| HQ State/Province | Ontario |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 10, 2023 (est.) |
| Last Earnings Release | Mar. 15, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 24, 2023.
Fundamentals
| Revenue (TTM) | -- |
| Total Expenses (TTM) | 25.54M |
| Net Income (TTM) | 0.1822M |
| Total Assets (Quarterly) | 37.18M |
| Total Liabilities (Quarterly) | 10.50M |
| Shareholders Equity (Quarterly) | 26.68M |
| Cash from Operations (TTM) | -24.46M |
| Cash from Investing (TTM) | 2.935M |
| Cash from Financing (TTM) | -34.93M |
Ratings
Profile
Edit
| Liminal Biosciences Inc is a clinical stage biopharmaceutical company focused on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic, and metabolic diseases using our drug discovery platform and a data driven approach. The company has active business operations in Canada and the United Kingdom. |
| URL | https://www.liminalbiosciences.com |
| Investor Relations URL | http://www.prometic.com/investors/ |
| HQ State/Province | Ontario |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 10, 2023 (est.) |
| Last Earnings Release | Mar. 15, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| LMNL Tweets |